SI trades 11.0% above Wall Street's consensus target of $19.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Shoulder Innovations, Inc. (SI) has a Wall Street consensus price target of $19.00, based on estimates from 3 covering analysts. With the stock currently trading at $21.35, this represents a potential downside of -11.0%. The company has a market capitalization of $441M.
Analyst price targets range from a low of $19.00 to a high of $19.00, representing a 0% spread in expectations. The median target of $19.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SI trades at a trailing P/E of -41.1x. Analysts expect EPS to grow +20.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
GMEDGlobus Medical, Inc. | $10.6B | $78.83 | $109.50 | +38.9% | Buy | 16.6x | 36 |
ATECAlphatec Holdings, Inc. | $1.4B | $9.38 | $18.00 | +91.9% | Buy | 29.3x | 18 |
XTNTXtant Medical Holdings, Inc. | $59M | $0.42 | — | — | — | — | — |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
ZBHZimmer Biomet Holdings, Inc. | $17.5B | $89.41 | $96.33 | +7.7% | Hold | 10.5x | 42 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
JNJJohnson & Johnson | $643.3B | $267.24 | $253.42 | -5.2% | Buy | 23.1x | 40 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
Quick answers to the most common questions about buying SI stock.
SI's consensus price target is $19, -11.0% below the current price of $21.35. The 3 analysts tracking SI see downside risk at present valuations.
SI has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $19 implies -11.0% downside from current levels.
SI's current price is $21.35 with a consensus target of $19 (-11.0% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $19 for SI, while the most conservative target is $19. The consensus of $19 represents the median expectation. These targets typically reflect 12-month expectations.
SI is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SI stock forecast based on 3 Wall Street analysts shows a consensus price target of $19, with estimates ranging from $19 (bear case) to $19 (bull case). The median consensus rating is "Buy".
Analysts are cautious on SI, with 0 Sell ratings and a price target of $19 (-11.0% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SI analyst price targets range from $19 to $19, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.